Epitope mapping is a method that is often employed to identify the antigen binding sites of an antibody. However, epitope mapping can also be used in other protein interactions with high affinity, including those with proteins, chemicals, and DNA. RayBiotech’s peptide array-based epitope mapping service uses high-quality peptides that are chemically synthesized, thereby negating many of the steps and time required with the traditional approach that involves recombinant cloning, expression, and purification of different regions of the target gene.
RayBiotech’s comprehensive epitope mapping service includes peptide design and synthesis, array printing, sample testing, and report generation. Just send us your samples, and we’ll send you the report!
In addition to custom epitope mapping arrays, RayBiotech offers pre-designed peptide panels for popular drug targets. For more information, please contact our technical support team at [email protected].
RayBiotech’s peptide-based epitope mapping arrays are prepared by first printing overlapping, chemically-synthesized peptides (> 95% purity) spanning the length of the protein-of-interest onto a glass slide surface in an arrayed format, with each peptide spotted in triplicate. Multiple positive and negative controls are also printed onto the array to monitor each incubation step. Purified antibodies or bodily fluids containing antibodies are then diluted and incubated on the peptide arrays, during which the antibodies specifically bind to the peptides displaying their sequence-of-interest. After unbound antibodies are washed off the array, a biotin-conjugated secondary antibody (e.g., anti-human IgG, mouse IgG) and a fluorescence dye-conjugated streptavidin molecule are added to the array to enable the detection of bound antibodies bound. Fluorescent signal is then captured using a laser scanner. Since the peptide sequence of each spot is known, the antibody’s potential epitope(s) can be ascertained.
Results are presented as a fluorescent scan of the array (Figure 1) and in a table format (Table 1).
RayBiotech would like to thank Dr. Clemens Duerrschmid (Baylor College of Medicine, Houston, TX) for allowing us to present this data.